Aptargroup is a global leader in providing innovative dispensing and sealing solutions that enhance the user experience across a variety of markets, including consumer products, pharmaceuticals, and food and beverage. The company specializes in designing and manufacturing a diverse range of delivery systems, such as pumps, sprays, and valves, which are tailored to meet the specific needs of its customers. By focusing on sustainability and advanced technology, Aptargroup plays a crucial role in improving the functionality and safety of products while also helping clients navigate complex regulatory environments. Their commitment to innovation and quality positions them as a trusted partner for brands seeking to enhance their product offerings and expand their market reach. Read More
AptarGroup, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announces the commencement of a clinical study to validate its proprietary SmartTrack™ platform. The platform was developed by Aptar’s drug services company, Nanopharm. If validated, SmartTrack™ aims to reduce the need for clinical studies in generic drug product approvals by proving it can accurately predict clinical outcomes – removing a major barrier for pharma companies and regulators and paving the way for wider patient access to medications. This validation would establish SmartTrack™ as a credible in-vitro-in-silico alternative to comparative clinical endpoint (CCEP) studies, and a reliable approach to derisking in vitro-pharmacokinetic (PK) only approaches, specifically for generic inhaled drug products.
AptarGroup, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, has achieved the Platinum level rating in recognition of its sustainability efforts from EcoVadis for the fifth consecutive year. The Platinum rating places Aptar among the top 1% of the more than 150,000 companies rated by EcoVadis across all industries.
AptarGroup, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, has been named one of Barron’s 100 Most Sustainable U.S. Companies for the seventh consecutive year and is ranked number 26 out of the top 100 companies for 2025.
AptarGroup, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, has been recognized for its leadership on climate change topics by the global environmental non-profit CDP, securing a place on its prestigious “A List.”
AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today reported strong fourth quarter results due to solid operational performance driven by top and bottom line improvements. Results were driven by sales growth in pharma solutions, increased demand for closures technologies and productivity gains across the company. Reported sales increased by 1% and core sales increased by 2% due to a negative currency effect. Aptar reported net income of $101 million for the quarter, a 62% increase from the prior year. In addition, the quarterly results benefited from a lower effective tax rate.
It's a mixed session on Wall Street, with major indices struggling for direction as investors hold their breath ahead of a key jobs report set for Friday morning. The S&P 500 and the Nasdaq 100 edged up 0.3%, while the Dow Jones slipped 0.1% and small caps held steady.
AptarGroup, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that the Board declared a quarterly cash dividend of $0.45 per share. The payment date is February 26, 2025, to stockholders of record as of February 5, 2025.
AptarGroup, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that it has been named one of America’s Most Responsible Companies 2025 by Newsweek for the sixth consecutive year. Aptar is ranked number 71 out of 600 U.S. companies.
AptarGroup, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced the dates and times of quarterly conference calls for the year. Any updates to these dates or times will be communicated in subsequent press releases.
AptarGroup, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced their participation at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025.
AptarGroup, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that it has been named a World’s Top Companies for Women 2024 by Forbes for the fourth consecutive year (formerly World’s Top Female Friendly Companies). Aptar is ranked 41 out of the 400 companies included on the list by Forbes and their partner Statista. For this ranking companies were evaluated in three categories including employer brand, public opinion and leadership.
AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today reported strong third quarter results due to solid operational performance and margin improvement across the company. Results were driven by growth in proprietary drug delivery systems, as well as increased demand for closure technologies. Reported sales and core sales increased by 2%, as currency and acquisition effects did not impact the quarter. Aptar reported net income of $100 million for the quarter, a 19% increase from the prior year.
